

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

OK

38



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07D 231/44, 487/04, A61K 31/415, C07D 231/38, 231/18, 231/52, 403/10, 409/10</p>	<p>A1</p>	<p>(11) International Publication Number: WO 94/13643 (43) International Publication Date: 23 June 1994 (23.06.94)</p>
<p>(21) International Application Number: PCT/US93/10359 (22) International Filing Date: 3 November 1993 (03.11.93) (30) Priority Data: 07/992,225 17 December 1992 (17.12.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/992,225 (CIP) Filed on 17 December 1992 (17.12.92) (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FARACI, William, Stephen [US/US]; 4 Jeremy Drive, East Lyme, CT 06333 (US). WELCH, Willard, McKowan, Jr. [US/US]; 116 Pequot Avenue, Mystic, CT 06355 (US). (74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).</p>	<p>(81) Designated States: AU, BR, CA, CZ, JP, KR, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.</p>	
<p>(54) Title: PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY</p> <p>(57) Abstract</p> <p>The pyrazoles and pyrazolopyrimidines of formula (I) wherein R₁, R₂, R₃, R₄ and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.</p> <div style="text-align: center;"> <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


5 Pyrazoles and pyrazolopyrimidines having CRF antagonist activity

This invention relates to pyrazoles and pyrazolopyrimidines, pharmaceutical compositions containing them, and methods of administering them to subjects in need of their corticotropin-releasing factor (CRF) antagonist activity.

CRF antagonists are mentioned in U.S. Patents 4,605,642 and 5,063,245 referring to peptides and pyrazolinones, respectively. The importance of CRF antagonists is set out in the literature, e. g. as discussed in U.S. Patent 5,063,245, which is incorporated herein by reference. A recent outline of the different activities possessed by CRF antagonists is found in M. J. Owens et al., Pharm. Rev., Vol. 43, pages 425 to 473 (1991), also incorporated herein by reference. Based on the research described in these two and other references, CRF antagonists are effective in the treatment of a wide range of diseases including stress-related illnesses, such as stress-induced depression, anxiety, and headache; abdominal bowel syndrome; inflammatory diseases; immune suppression; human immunodeficiency virus (HIV) infections; Alzheimer's disease; gastrointestinal diseases; anorexia nervosa; hemorrhagic stress; drug and alcohol withdrawal symptoms; drug addiction, and fertility problems.

The compound of formula I below wherein A is C=O, R₁ is amino, R₂ is methylthio, R₃ is 2-chlorophenyl, and R₄ is 2,4,6-trichlorophenyl is a commercial compound of no known utility.

The present invention relates to a compound of the formula



and the acid addition salts thereof, wherein

A is C=O or SO₂, or A and R₁ together with the carbons to which they are attached form pyrimidinyl or 5-pyridyl which may be substituted by R₅ which is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, hydroxy, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), SH, S(O)_n(C₁-C₆ alkyl) wherein n = 0, 1 or 2, where in said C₁-C₆ alkyl may be substituted by from 1 to 3 substituents R₆ which is hydroxy,

-2-

amino, C₁-C₃ alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NH(C=O)CH₃, fluoro, chloro, bromo or C₁-C₃ thioalkyl;

R₁ is hydrogen, C₁-C₆ alkyl, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), wherein said C₁-C₆ alkyl may be substituted by from 1 to 3
5 substituents R₆ as defined above;

R₂ is hydrogen, C₁-C₆ alkyl, hydroxy, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), SH, S(O)_n(C₁-C₆ alkyl) wherein n = 0, 1, or 2, cyano, hydroxy, carboxy, or amido, wherein said alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, NH(C=O)(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl),
10 (C=O)O(C₁-C₆ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R₃ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, pyridinyl, tetrazolyl, or 9 to 12 membered bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkanoyl, phenyl or phenylmethyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, C₁-C₆ alkyl, C₁-C₆ alkoxy, or trifluoromethyl, or one of cyano, nitro, amino, NH(C₁-C₆ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NHSO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; and
20

R₄ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, pyridinyl, tetrazolyl, or 3 to 8-membered cycloalkyl or 9 to 12-membered bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkanoyl, phenyl or phenylmethyl, wherein each of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, trifluoromethyl, C₁-C₆ alkyl or C₁-C₆ alkoxy, or n of cyano, nitro, amino, NH(C₁-C₆
30

- alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NH₂SO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl;
- 5 provided that (1) R₄ is not unsubstituted phenyl; (2) when R₁ is amino, R₂ is methylthio, R₄ is 2,4,6-trichlorophenyl, and A is C=O, then R₃ is not 2-chlorophenyl; and (3) R₁ and R₂ are not both hydrogen.

- More specific compounds of the formula I include those wherein R₃ is phenyl substituted independently with one or two of fluoro, chloro, bromo, methyl, trifluoromethyl, nitro, C₁-C₆ alkyl, C₁-C₆ alkyloxy, SO₂NH₂, SO₂NH(C₁-C₆ alkyl), SO₂N(C₁-C₆ alkyl)₂, or R₃ is primary, secondary or tertiary alkyl of from 4-9 carbon atoms wherein said C₄-C₉ alkyl may contain from one to two double or triple bonds and may be substituted by from 1 to 3 substituents R₆ which is hydroxy, amino, C₁-C₃ alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NH(C=O)CH₃, fluoro, chloro, bromo, or C₁-C₃ thioalkyl.
- 10
- 15

More specific compounds of the formula I are those wherein A is C=O, those wherein R₁ is amino, methylamino or dimethylamino; those wherein R₂ is ethyl or methylthio and those wherein R₄ is 2,4,6-trichlorophenyl, 2,4,6-trimethylphenyl, 2,6-dichloro-4-trifluoromethylphenyl or 4-bromo-2,6-dimethylphenyl.

- 20 More specific compounds of formula I further include those wherein R₃ is phenyl which may be substituted at positions 2 or 5 with one or two of methyl, C₂-C₆ straight-chain or branched alkyl, trifluoromethyl, fluoro, chloro, bromo or nitro, those wherein A and R₁ together form a pyrimidine ring, such that the bicyclic structure formed is pyrazolo[3,4-d]pyrimidine, and R₆ is substituted at the 6 position; and those wherein R₃ is phenyl substituted independently with one or two of fluoro, chloro, bromo, methyl, trifluoromethyl, nitro, C₁-C₆ alkyl, C₁-C₆ alkyloxy, SO₂NH₂, SO₂NH(C₁-C₆ alkyl), or SO₂N(C₁-C₆ alkyl)₂, R₄ is 2,4,6-trichlorophenyl, 2,4,6-trimethylphenyl, 2,6-dichloro-4-trifluoromethylphenyl or 4-bromo-2,6-dimethylphenyl, and R₂ is methylthio, methyl or ethyl.
- 25

- 30 More specific compounds of formula I also include those wherein R₃ is phenyl substituted independently with one or two of fluoro, chloro, bromo, methyl, trifluoromethyl, nitro, C₁-C₆ alkyl, C₁-C₆ alkyloxy, SO₂NH₂, SO₂NH(C₁-C₆ alkyl), SO₂N(C₁-C₆ alkyl)₂, or R₃ is primary, secondary or tertiary alkyl of from 4-9 carbon

atoms wherein said C_4-C_9 alkyl may contain from one to two double or triple bonds and may be substituted by from 1 to 3 substituents R_6 which is hydroxy, amino, C_1-C_3 alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, $NH(C=O)CH_3$, fluoro, chloro, bromo or C_1-C_3 thioalkyl; R_4 is 2,4,6-trichlorophenyl, 2,4,6-trimethylphenyl, 2,6-dichloro-4-trifluoromethylphenyl or 4-bromo-2,6-dimethylphenyl; R_1 is amino, methylamino or dimethylamino; and R_2 is methylthio or ethyl.

The most preferred compounds of the invention are

- [5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methylsulfanyl-1H-pyrazol-4-yl]-(2,5-dimethylphenyl)methanone,
- 10 [5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methylsulfanyl-1H-pyrazol-4-yl]-(2,5-bis-trifluoromethylphenyl)methanone,
- [5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methylsulfanyl-1H-pyrazol-4-yl]-(5-isopropyl-2-methylphenyl)methanone,
- [5-amino-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]-(5-isopropyl-2-methylphenyl)methanone, and
- 15 [5-amino-1-(4-bromo-2,6-dimethylphenyl)-3-methylsulfanyl-1H-pyrazol-4-yl]-(2,5-dibromophenyl)methanone.

The invention also relates to a composition for the treatment of illnesses induced or facilitated by corticotropin releasing factor which comprises a compound of the formula I as defined above or the known compound of formula I wherein A is $C=O$, R_1 is amino, R_2 is methylthio, R_3 is 2-chlorophenyl, and R_4 is 2,4,6-trichlorophenyl, in an amount effective in the treatment of said illnesses, and a pharmaceutically acceptable carrier, and to a composition for the treatment of inflammatory disorders, stress and anxiety related disorders including stress-induced depression and headache, abdominal

25 bowel syndrome, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, which comprises a compound of the formula I as well as the known compound, both as defined above in an amount effective in the treatment of said disorders, and a pharmaceutically acceptable carrier. More specific and most preferred compositions for the treatment of such illnesses and disorders comprise a more specific and most preferred compound of formula I as defined above.

30

The invention further includes a method for the treatment of illnesses induced or facilitated by corticotropin releasing factor by administering to a subject in need of such treatment a compound of formula I or the known compound, both as defined above, and a method for the treatment of stress and anxiety related disorders, including stress-induced depression and headache, abdominal bowel syndrome, inflammatory disorders, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, particularly depression, by administering to a subject in need of such treatment a compound of formula I as well as the known compound, both as defined above. More specific and most preferred methods for the treatment of such illnesses and disorders comprise a more specific and most preferred compound of formula I as described above.

Whenever reference is made herein to C₁-C₆ alkyl, a straight or branched chain alkyl of one to six carbon atoms is meant, such as methyl, ethyl, isopropyl or hexyl.

Whenever reference is made herein to C₁-C₆ alkyl, in the definition of R₅ and R₁, this includes unsaturated C₂-C₆ alkyl, such as C₂-C₆ alkyl having one double or triple bond, C₃-C₆ alkyl having two double bonds, and C₄-C₆ alkyl having two triple bonds.


Whenever reference is made hereafter to a compound of formula I, this includes the known compound of formula I as described above.

Whenever R₃ is a heterocyclic group, the attachment to A, defined above, is through one of the carbons in the heterocyclic group. Similarly, when R₄ is a heterocyclic group, the attachment to the nitrogen in the pyrazole ring is through one of the carbons in the heterocyclic group.

Whenever reference is made herein to 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl containing one to three of O, S or N-Z, it is understood that the oxygen and sulfur ring atoms are not adjacent to each other.

The compounds of the formula I wherein R₁ is amino or C₁-C₆ alkyl, and R₂ is methylthio, having the formula II (not shown), may be prepared from a compound of the formula

-6-




5

wherein R_{10} is cyano or $C(O)(C_1-C_6 \text{ alkyl})$ and A and R_3 are as defined above with reference to formula I, by reaction with a compound of the formula



- 10 wherein R_4 is as defined with reference to formula I. This reaction is generally carried out in a polar solvent, such as a C_1-C_6 alcohol. The reaction temperature generally ranges from about $20^\circ C$ to about $160^\circ C$, and is conveniently the reflux temperature of the reaction mixture.

15 The compounds of formula III may be prepared by treating a compound of the formula




- 20 with a base such as sodium hydride, in the presence of carbon disulfide followed by reaction of the formed intermediate with methyl iodide in a reaction solvent such as dimethylsulfoxide.

The compounds of formula IV are readily available or may be obtained by methods known in the art.

The compounds of formula V may be prepared by known methods.


- 25 The compounds of the formula I wherein R_2 is alkoxy, amino, or mono- or disubstituted amino may be prepared by using the above procedure with R_4NHNH_2 from the corresponding compounds of the formula



30


wherein A and R₃ are as defined with reference to formula I, R₁₀ is as defined with reference to formula III, and R, R' and R'' are each hydrogen or C₁-C₆ alkyl in accordance with the definition of R₂ above.

The compounds of the formula I wherein R₁ is C₁-C₆ alkoxy or C₁-C₆ alkylthio
 5 and R₂ is C₁-C₆ alkyl may be prepared from a compound of the formula



wherein R_x is chloro or bromo, R₂ is C₁-C₆ alkyl, and R₃, R₄ and A are as defined above with reference to formula I, with a C₁-C₆ alcohol or C₁-C₆ mercaptan in the presence of
 15 a base. The reaction is generally carried out in a polar solvent such as ethanol or t-butanol at temperatures from about 20°C to about 160°C and conveniently room temperature.


The compounds of the formula IX may be prepared by treating a compound of the formula



with a halogenating agent such as thionyl chloride or bromide, or phosphorous oxychloride or pentachloride, or phosphorous oxybromide or pentabromide. The reaction may be carried out without a solvent or in an aprotic solvent such as
 30 methylene chloride, or dichloroethane at temperatures of about 0°C to about 100°C.


Compounds of formula X may be prepared by treating compounds of the formula

-8-




with an activated derivative of a carboxylic or sulfonic acid of the formula $R_3\text{AOH}$, such as an acid chloride of the formula $R_3\text{ACl}$ wherein R_3 and A are as defined with reference to formula I, in the presence of calcium hydroxide in an aprotic solvent such as dioxane as described in Jensen, Acta Chem. Scand., 13, 1668-1670 (1959) at temperatures of from about 20°C to about 100°C. Compounds of the formula XI are known in the art.

The compounds of the formula I wherein R_1 is $\text{C}_1\text{-C}_6$ alkoxy or $\text{C}_1\text{-C}_6$ alkylthio and R_2 is $\text{C}_1\text{-C}_6$ alkylthio may be prepared from a compound of the formula




20 wherein R_Y is chloro or bromo and R_3 , R_4 and A are as defined above with reference to formula I, with a $\text{C}_1\text{-C}_6$ alcohol or $\text{C}_1\text{-C}_6$ mercaptan in the presence of a base. The reaction is generally carried out in a polar organic solvent such as ethanol or t-butanol at temperatures from about 20°C to about 160°C, conveniently room temperature.

25 The compounds of the formula XII may be prepared from a compound of the formula




by reaction with a halogenating agent such as thionyl chloride or bromide, or phosphorous oxychloride or pentachloride, or phosphorous oxybromide or pentabromide. The reaction may be carried out with a solvent or in an aprotic solvent such as methylene chloride or dichloroethane at temperatures of about 0°C to about 100°C.

The compounds of the formula XIII may be prepared by treating a compound of the formula



15 with activated benzoic or sulfonic acid derivatives, conveniently an acid chloride, in the presence of calcium hydroxide in an aprotic solvent such as dioxane as described in the above reference by Jensen.


The compounds of the formula XIV may be prepared by treating a compound of the formula



25 wherein R₂ is chloro, bromo with a C₁-C₆ mercaptan in the presence of a base. The reaction is generally carried out in a polar organic solvent such as t-butanol at temperatures from about 20°C to about 160°C, conveniently the reflux temperatures of the reaction mixture.


30 The compounds of the formula XV may be prepared from compounds of the formula

-10-




with a halogenating agent such a thionyl chloride or bromide, or phosphorous
 oxychloride or pentachloride, or phosphorous oxybromide or pentabromide. The
 reaction may be carried out without a solvent or in an aprotic solvent such as
 10 methylene chloride or dichloroethane at temperatures of about 0°C to about 100°C.

The compounds of the formula I wherein R₁ is C₁-C₆ alkoxy or C₁-C₆ alkylthio
 and R₂ is C₁-C₆ alkoxy may be prepared from a compound of the formula



20 wherein R_{xx} is chloro or bromo, R₂ is C₁-C₆ alkoxy and R₃, R₄ and A are as defined
 above with reference to formula I, with a C₁-C₆ alcohol or C₁-C₆ mercaptan in the
 presence of a base. The reaction is generally carried out in a polar organic solvent
 such as ethanol or t-butanol at temperatures from about 20°C to about 160°C,
 conveniently the reflux temperature of the reaction mixture.


25 The compounds of the formula XVII may be prepared from a compound of the
 formula



-11-

by reaction with a halogenating agent such as thionyl chloride or bromide, or phosphorous oxychloride or pentachloride, or phosphorous oxybromide or pentabromide. The reaction may be carried out without a solvent or in an aprotic solvent such as methylene chloride, or dichloroethane at temperatures of about 0°C to about 100°C.


The compounds of the formula XVIII may be prepared by treating a compound of the formula



with an activated derivative of a carboxylic or sulfonic acid of the formula $R_3\text{AOH}$, conveniently an acid chloride of the formula $R_3\text{ACl}$ wherein R_3 and A are as defined above with reference to formula I, in the presence of calcium hydroxide in an aprotic solvent such as dioxane as described by Jensen in the reference cited above.


The compounds of the formula XIX may be prepared by treating a compound of the above formula XV with an alcohol in the presence of a base. The reaction is generally carried out in a polar organic solvent such as ethanol at temperatures from about 20°C to about 160°C, conveniently the reflux temperatures of the reaction mixture.

The compounds of the formula I wherein R_1 is amino and R_2 is $\text{O}(\text{C}_1\text{-C}_6\text{alkyl})$ may be prepared by reacting a compound of the formula




wherein R_3 , R_4 and A are as defined above with reference to formula I, with hydrazine in a solvent such as a $\text{C}_1\text{-C}_6$ alcohol, conveniently at the boiling point of the solvent.

The compounds of the formula XX may be prepared by treating a compound of the formula



- 10 wherein R_3 , R_4 and A are as defined above with reference to formula I, with an alkylating agent such as di(C_1 - C_6 alkyl) sulfate, and a base such as sodium hydride, in a solvent such as dimethylsulfoxide.

The compounds of the formula XXI may be prepared by treating a compound of the formula




- 25 with an activated derivative of a carboxylic or sulfonic acid of the formula R_3AOH such as an acid chloride of the formula R_3ACl , wherein R_3 and A are as defined with reference to formula I, in the presence of a Lewis acid such as aluminum chloride in an aprotic solvent such as methylene chloride, dichloroethane, or tetrachloroethane, at temperatures of about $0^\circ C$ to about $150^\circ C$.

The compounds of the formula XXII may be prepared by treatment of a compound of the formula

30


-13-



with phthalic anhydride in acetic acid at the boiling point of the solvent.


The compounds of the formula XXIII may be prepared by contacting cyanoacetyl chloride with $R_4\text{NHNH}_2$ in the presence of a base followed by heating the resulting
10 hydrazide at reflux in alcoholic solution in the presence of a base.

The compounds of formula I wherein A and R_1 are taken together to form pyrimidinyl have the formula



20

wherein R_2 , R_3 , R_4 , and R_5 are as defined above with reference to formula I. These compounds may be prepared by cyclization of a compound of the above formula I wherein A is C=O and R_1 is amino with a compound of the formula




wherein R_5 is as defined with reference to formula I. This reaction is generally carried out at 100 to 250°C, and conveniently at the reflux temperature of the compound XXV.

The compounds of formula I wherein A and R_1 are taken together to form 5-
30 pyridyl have the formula



10



Reaction Scheme 1



25

30

-15-



15

The compounds of formula XXIX are prepared by reacting a ketone of the formula XXVII with a compound of the formula XXVIII in a suitable solvent such as tetrahydrofuran in the presence of a base such as sodium hydride. The reaction is conveniently carried out at the reflux temperature of the reaction mixture.


20 The compound XXIX is reacted with a compound of the formula $R_2C(OCH_3)_2$ to form the compound XXX. The reaction is carried out in a suitable solvent such as ethyl acetate, conveniently at the reflux temperature of the reaction mixture. The wavy line — in formula XXX indicates that either isomer of this compound is included, in accordance with accepted convention for indicating stereoisomers.

25 The compound XXXI is prepared by reacting compound XXX with a hydrazine of the formula H_2NNHR_4 wherein R_4 is as defined with reference to formula I. The reaction is carried out in a suitable solvent such as ethanol, conveniently at the reflux temperature of the reaction mixture.


30 The compounds of formula XXVI wherein R_5 is linked to position 6 is formed by first reacting compound XXXI with hydrazine hydrate in a suitable solvent such as ethanol, conveniently at the reflux temperature of the reaction mixture. The compound XXXII is separated from precipitated phthalhydrazide and taken up in an organic solvent

such as toluene. The compound XXVI is formed by dehydrogenation of compound XXXII with palladium over carbon.


Reaction Scheme 1 shows the preparation of compounds XXVI wherein R_5 is in the 6-position. A similar reaction sequence may be followed to prepare compounds XXVI wherein R_5 is in the 7-position by replacing compound XXVIII by a compound of the formula



15 The compounds of formula I wherein A is C=O and R_1 and R_2 are the same group R_7 may be prepared by reacting a β -ketone of the formula



20 with the hydrazine of the formula IV as defined above to form a pyrazole compound of the formula




30 The reaction proceeds at reflux in an appropriate solvent such as ethanol. After bromination of the pyrazole compound, e.g. with bromine in acetic acid, to form the corresponding 4-bromo derivative and conventional metallation, e.g. with *t*-butyl lithium, at -78°C in tetrahydrofuran, a suitably activated R_3 carboxylic acid such as the acid chloride $R_3\text{C(O)Cl}$ is added to give the desired compound I.

-17-


The compounds of formula I wherein A is C=O and R₁ and R₂ are not the same, and wherein R₁ or R₂ is attached through a C₂H₄ fragment, may be prepared from a pyranone of the formula

5



wherein R₃ is as defined above, and R₂ is as defined above when R₁₁ is C₃-C₆ alkyl which may be substituted by 1 to 3 of R₆, or R₂ is R₁ when R₁₁ is C₃-C₆ alkyl which may be substituted by one to three of hydroxy, amino, carboxy, amido, NH(C=O)(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), (C=O)O(C₁-C₆), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro. The compound XXXIV is reacted with a hydrazine of the formula H₂NNHR₄ wherein R₄ is as defined above to form compounds of the formulae


15



20

which on dehydration and hydrogenation result in compounds of the formulae


25




The compounds of the formula I wherein A is C=O and R₂ is O(C₁-C₆ alkyl) may be prepared by reacting a hydrazine of the formula R₄NHNH₂ with a compound of the formula (A) in a suitable solvent

30

5



(A)



(B)

- 10 such as THF or methylene chloride and cyclization of the resulting hydrazide with heat to give the intermediate (B). This compound may be reacted with an activated carboxylic acid derivative such as the acid chloride $R_3(C=O)Cl$ in the presence of a Lewis acid such as aluminum trichloride in a solvent such as ethylene dichloride at temperatures of from about $-10^{\circ}C$ to about $80^{\circ}C$. The formed compound of formula
- 15 I wherein R_2 is hydroxy may be reacted with $(C_1-C_6 \text{ alkyl})L$ wherein L is a leaving group such as chloro, bromo, or tosylate and $C_1-C_6 \text{ alkyl}$ may be substituted in accordance with the substituents in the definition of R_2 .

Those compounds of formula I wherein R_1 is C_1-C_6 alkylamino or $di(C_1-C_6 \text{ alkyl})amino$ may be prepared from corresponding compounds of formula I wherein R_1

20 is amino. When R_1 is methylamino or dimethylamino, reaction is with a methylating agent such as methyl iodide. When R_1 is C_2-C_6 alkylamino or $di(C_2-C_6 \text{ alkyl})amino$, reaction is with an alkylating agent such as $C_2-C_6 \text{ alkyl}-L$ wherein L is a leaving group such as chloro, bromo, tosylate, or mesylate. Both the methylation and the C_2-C_6 alkylation is in the presence of a base such as sodium hydride and a solvent such as

25 tetrahydrofuran, dimethyl formamide or dimethyl sulfoxide.

The acid addition salts are prepared in a conventional manner by treating a solution or suspension of the free base of formula I with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization techniques are employed in isolating the salts. Illustrative of suitable acids are acetic,

30 lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p-toluenesulfonic, and related acids.

The compound of the invention may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formula I and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

For parenteral administration, solutions of the novel compound of formula I in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

Additionally, it is possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may be done by way of creams, jellies, gels, pastes and ointments, in accordance with standard pharmaceutical practice.

The effective dosage for the compound of formula I depends on the intended route of administration and other factors such as age and weight of the patient, as generally known to a physician. The dosage also depends on the illness to be treated, although in general the daily dosage will range from about 0.1 to 50 mg/kg of the body weight of the patient. More specifically, the daily dosage for stress-induced illnesses will generally range from about 0.1 to 50 mg/kg of the body weight of the patient to be treated, for treatment of inflammatory diseases about 0.1 to about 100 mg/kg will be needed, for Alzheimer's disease, about 0.1 to about 50 mg/kg, as well as for gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, and drug and alcohol withdrawal symptoms.

The methods for testing the compounds for formula I for their CRF antagonist activity are according to the procedures of Endocrinology, 116, 1653-1659 (1985) and Peptides, 10, 179-188 (1985) which determine the binding activity of a test compound to a CRF receptor. The binding activity for the compounds of formula I generally ranges from about 0.2 nanomolar to about 10 micromolar.

The following abbreviations are used in the Examples: Ph=phenyl; iPr=isopropyl; HRMS=high resolution mass spectrum.

Example 1

A. 2-Bromo-2',5'-dimethylacetophenone.

A mixture of 10.60 g (0.10 mol) of para-xylene and 16.53 g (0.105 mol) of α -bromoacetyl chloride in 300 mL of 1,2-dichloroethane was cooled in an ice bath under an atmosphere of dry N₂ and treated portionwise with 14.15 g (0.106 mol) of aluminum chloride. The reaction mixture was stirred for 30 minutes at 0 - 5°C and then for 2.5 hours at room temperature. The mixture was then poured onto ice and the aqueous layer was acidified with concentrated HCl. The organic layer was separated and the aqueous layer was extracted twice with methylene dichloride. The combined organic extracts were dried with brine solution and with magnesium sulfate. The solvent was evaporated to give 23.87 g of an amber oil which was for use in the next reaction without further purification.

B. 2-Cyano-2',5'-dimethylacetophenone.

The product of the above reaction (approximately 0.10 mol) was dissolved in 300 mL of ethanol and was treated with a solution of 16.25 g (0.25 mol) of potassium cyanide in 30 mL of water and the resulting mixture was refluxed for 90 minutes. After

cooling, the ethanol was stripped from the mixture on the rotary evaporator and the residues were made slightly acidic with concentrated hydrogen chloride. The product was extracted into ethyl acetate using precautions to avoid escape of hydrogen cyanide. The organic extracts were dried with brine and with magnesium sulfate and
5 evaporated to a gummy semi-solid. This was triturated repeatedly with hot hexane which, on cooling, deposited needles to give the desired product, 8.50 g (49% for the two reactions), m.p. 75 - 76°C.

C. 3,3-Bis-methylthio-2-(2,5-dimethylbenzoyl)-acrylonitrile.

A solution of 4.96 g (28.6 mmol) of 2-cyano-2',5'-dimethylacetophenone in 120
10 mL of dry dimethyl sulfoxide and 3.43 mL (57.3 mmol) of carbon disulfide in a flame-dried 3-neck round bottom flask under dry nitrogen was stirred at 15 - 18°C while 1.41 g (58.7 mmol) of oil free sodium hydride was added in 5 portions. The resulting deep red solution was stirred for 1 hour at 18°C and then cooled to 15°C whereupon 3.92 mL (8.95 g, 63.0 mmol) of methyl iodide was added dropwise. The temperature rose
15 to about 22°C during the addition. After stirring for 2 hours at room temperature, the reaction mixture was poured into cold water and the aqueous layer was extracted three times with ethyl acetate. The combined extracts were washed three times with water and then dried with brine and magnesium sulfate. Evaporation gave 8.96 g of the title compound as a heavy orange oil which crystallized in the refrigerator. The analytical
20 sample crystallized from ethanol, m.p. 74.5 - 75.5°C.

D. 5-Amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(2,5-dimethylbenzoyl)-3-methylthiopyrazole.

A suspension of 7.94 g (28.6 mmol) of the product of step C and 7.01 g (28.6 mmol) of 2,6-dichloro-4-trifluoromethylphenylhydrazine in 100 mL of ethanol was heated
25 at reflux for 2 hours, solution occurring as the reaction mixture was warmed. Then the ethanol was mostly removed on the rotary evaporator and the residues were partitioned between dilute aqueous hydrogen chloride solution and ethyl acetate. The organic phase was washed once with water and with brine, then dried with magnesium sulfate and treated with decolorizing carbon. The filtered solution was evaporated and the
30 residues crystallized from 10:1 hexane/ethyl acetate to give 12.00 g (88%) of the title product in two crops, m.p. 130 - 132°C.

Example 25-Methylamino-4-(2-chlorobenzoyl)-3-methylthio-1-(2,4,6-trichlorophenyl)pyrazole and 5-dimethylamino-4-(2-chlorobenzoyl)-3-methylthio-1-(2,4,6-trichlorophenyl)pyrazole.


- 5 A mixture of 0.50 g (1.16 mmol) of 5-amino-4-(2-chlorobenzoyl)-3-methylthio-1-(2,4,6-trichlorophenyl)pyrazole in 5 mL of tetrahydrofuran was treated with 50 mg (1.16 mmol) of sodium hydride and stirred at room temperature for 30 minutes. Then 0.75 ml (1.71 g, 12.0 mmol) of methyl iodide was added dropwise and the reaction mixture was stirred for 60 minutes at room temperature. The reaction mixture was then
- 10 quenched with water and the products were extracted into ethyl acetate. Concentration of the dried solution and chromatography on silica gel with mixture of hexane and ethyl acetate gave the less polar dimethylamino title compound (300 mg, 54%) as a white foam. Anal. Calcd. for $C_{19}H_{15}ON_3SCl_4$: C, 48.02; H, 3.18; N, 8.88. Found: C, 47.84; H, 3.09; N, 9.01.
- 15 The more polar monomethyl title compound was isolated from the column in like manner as a white foam (34 mg, 6%). Anal. Calcd. for $C_{18}H_{13}ON_3SCl_4$: C, 46.88; H, 2.84; N, 9.11. Found: C, 46.54; H, 2.89; N, 9.07.

Example 35-Amino-4-(2-methoxybenzoyl)-3-methylthio-1-(2,4,6-trichlorophenyl)pyrazole.

- 20 To a solution of 2-methoxyphenylmagnesium bromide prepared from 18.7 g (0.10 mol) of 2-bromoanisole and 2.43 g (0.10 mol) of magnesium turnings in ether under dry nitrogen was added 1.6 g (5.0 mmol) of 5-amino-4-cyano-3-methylthio-1-(2,4,6-trichlorophenyl)pyrazole and the resulting mixture was stirred and refluxed for 16 hours. Upon cooling, the reaction was decomposed with 50 mL of saturated
- 25 ammonium chloride solution. The organic phase was extracted with aqueous hydrogen chloride and the acidic extract was treated with 10 mL of concentrated hydrogen chloride and heated at 80 - 90°C for 10 minutes after which the mixture was cooled and made alkaline. Extraction with methylene dichloride and chromatography of the extracts with mixtures of hexane and ethyl acetate gave 313 mg (14%) of the title
- 30 compound, m.p. 200-202°C. Anal. Calcd. for $C_{18}H_{14}O_2N_3SCl_3$: C, 48.82; H, 3.18; N, 9.49. Found: C, 48.54; H, 3.32; N, 9.09.

Example 4A. 5-Amino-3-methyl-1-(2,4,6-trichlorophenyl)pyrazole.

To a solution of 0.51 g (22.0 mmol) of sodium in methanol was added 1.66 g (20.0 mmol) of 5-methylisoxazole. The reaction mixture was refluxed for 8 hours and then stirred overnight at room temperature. Then 4.23 g (20.0 mmol) of 2,4,6-




for 4
nued
ogen
rine,
132-
2190
of 1-
d in
After
was
21 g
after
the
intermediate on silica gel TLC plates developed with 1:1 hexane ethyl acetate and a
distinctly different 300 MHz proton NMR spectrum.

B. 5-(2-Chlorobenzamido)-4-(2-chlorobenzoyl)-3-methyl-1-(2,4,6-trichlorophenyl)pyrazole.

A suspension of 2.34 g (17.50 mmol) of aluminum trichloride in 20 mL of 1,1,2,2-tetrachloroethane was treated with 2.02 mL (2.78 g, 15.9 mmol) of 2-chlorobenzoyl chloride and the resulting solution was stirred for 20 minutes at room temperature. Then 2.00 g (7.23 mmol) of the product of Step A was added and the reaction mixture was refluxed for 16 hours. The cooled reaction mixture was poured over ice and the insolubles were filtered off and washed with ethyl acetate. The organic layer was separated and the aqueous was washed twice with ethyl acetate. The combined organic layers were dried over magnesium sulfate and evaporated. The residues were chromatographed on silica gel, eluting with 4:1 hexane ethyl acetate to give 2.05 g (51%) of the title product, an amorphous foam. Anal. Calcd. for $C_{24}H_{14}O_2N_3Cl_5$: C, 52.06; H, 2.55; N, 7.59. Found: C, 52.11; H, 2.57; N, 7.27.

C. 5-Amino-4-(2-chlorobenzoyl)-3-methyl-1-(2,4,6-trichlorophenyl)pyrazole.

A solution of 1.94 g (3.50 mmol) of the product of Step B in 20 mL of glacial acetic acid was treated with 20 mL of 48% hydrogen bromide for 8 hours. The cooled reaction mixture was treated with water which was separated by filtration, washed with water and product, 1.45 g (100%), m.p. softens about 210°C and melts for $C_{17}H_{11}ON_3Cl_4$: 412.9656. Found: 412.9722.



Example 5

5-Methylamino-4-(2-chlorobenzoyl)-3-methyl-1-(2,4,6-trichlorophenyl)pyrazole and 5-dimethylamino-4-(2-chlorobenzoyl)-3-methyl-1-(2,4,6-trichlorophenyl)pyrazole.

A solution of 0.208 g (0.5 mmol) of the compound of Example 4C in 20 mL of tetrahydrofuran (THF) was stirred in an ice/water bath while 5.0 mL of 1.0 M sodium hexamethyldisilazide in THF was added followed by 0.5 mL (1.14 g, 8 mmol) of methyl iodide. The reaction mixture was then stirred overnight at room temperature. The reaction mixture was poured into water and the products were extracted into ethyl acetate, dried and concentrated. The residues were chromatographed on silica gel using 5:1 hexane/ethyl acetate as eluent to give the less polar dimethylamino title compound, 52 mg (23%), m.p. 108-109°C (ether/pentane).

The more polar product likewise crystallized from ether/pentane to give 39 mg (18%) of the monomethylamino title compound, m.p. 174-175°C.

Example 6

5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(2,5-dimethylbenzoyl)-3-(n-propyl)pyrazole.

A solution of 0.52 g (3.0 mmol) of 2,5-dimethylbenzoylacetonitrile, 0.45 g (3.0 mmol) of trimethylorthobutyrate and 0.632 g (0.58 mL, 6.2 mmol) of acetic anhydride in 5.0 mL of ethyl acetate was refluxed overnight and then cooled. The solvents were removed in vacuo and the residues were dissolved in 10 mL of ethanol. One-half of this solution, containing 1.5 mmol of 1-cyano-1-(2,5-dimethylbenzoyl)-3-methoxy-1-pentene was mixed with 0.7 mL (0.51 g, 5.0 mmol) of triethylamine and 0.37 g (1.50 mmol) of 2,6-dichloro-4-trifluoromethylphenylhydrazine and refluxed for 2.5 hours. The reaction mixture was cooled and partitioned between dilute hydrogen chloride and ethyl acetate. The organic phase was washed with water and then dried with brine and with magnesium sulfate. The solvent was evaporated to give an oil which was

chromatographed on silica gel by the flash method eluting with 4:1 hexane/ethyl acetate to give the title compound as an amorphous foam. Anal. Calcd. for $C_{22}H_{20}ON_3Cl_2F_3$, 469.0935. Found: 469.0889.

Example 7

5 A. 5-Amino-3-hydroxy-1-(2,4,6-trichlorophenyl)-pyrazole.

Cyanoacetic acid (8.5 g, 0.10 mol) in 200 mL of dry ether was treated with 20.8 g (0.10 mol) of phosphorous pentachloride, warmed briefly to reflux and let cool to room temperature at which time all of the phosphorous pentachloride, had dissolved. After a small amount of insoluble material was removed by filtration, the ether was
10 removed on the rotary evaporator. Then 100 mL of toluene was added and stripped to remove phosphorous oxytrichloride. The residual pale yellow oil was immediately dissolved in 50 mL of cold methylene dichloride and added to a cold suspension of 21.15 g (0.10 mol) of 2,4,6-trichlorophenyldiazine in 14.0 mL of triethylamine and 100 mL of methylene dichloride, keeping the temperature below 20°C by use of an ice bath.
15 The reaction mixture was allowed to warm to room temperature and stirred for one hour. Then 500 mL of cold water was added. The precipitated solid was filtered and washed with water and with a little methylene dichloride to give the intermediate 2-cyano-N-(2,4,6-trichlorophenyl)acetylhydrazide, 14.92 g (54%), m.p. 166-168°C. Anal. Calcd. for $C_9H_6ON_3$: C, 38.81; H, 2.17; N, 15.09. Found: C, 38.83; H, 2.06; N, 14.81.

20 This material (14.92 g, 53 mmol) was dissolved in a solution of 2.80 g (0.12 mol) of sodium in 200 mL of methanol and refluxed for 4 hours. After stirring overnight at room temperature, the methanol was mostly evaporated and the residues were poured into water. The aqueous layer was extracted with ether and was then acidified with concentrated hydrogen chloride. The product was extracted into ethyl acetate. The
25 extracts were dried with brine and magnesium sulfate and evaporated to give a foam which crystallized from ether to give 12.28 g (93%) of the title product, m.p. 221 - 223°C. Anal. Calcd. for $C_9H_6ON_3$: C, 38.81; H, 2.17; N, 15.09. Found: C, 38.81; H, 2.16; N, 14.84.

B. 3-Hydroxy-5-phthalimido-1-(2,4,6-trichlorophenyl)pyrazole.

30 A mixture of 4.50 g (18.0 mmol) of the compound of Step A and 2.81 g (19.0 mmol) of phthalic anhydride in 40 mL of glacial acetic acid was refluxed for 4 hours and stirred overnight at room temperature. About two volumes of water were added dropwis and the resulting solid was filtered and washed with water. Th damp solid

was taken up in a little ethanol, filtered and washed with a little ethanol and ether, and air dried to give the title compound, 5.11 g (69%), m.p. 295 - 298°C(dec). Anal. Calcd. for $C_{17}H_8O_3N_3Cl_3$: C, 49.97; H, 1.97; N, 10.28. Found: C, 49.28; H, 1.95; N, 10.06.

C. 4-(2-Chlorobenzoyl)-3-hydroxy-5-phthalimido-1-(2,4,6-trichlorophenyl)pyrazole.


Aluminum trichloride (2.34 g, 17.6 mmol) was added to a solution of 2-chlorobenzoyl chloride in 60 mL of 1,1,2,2-tetrachloroethane and the resulting mixture was stirred for 30 minutes at room temperature. Then 2.87 g of the compound of Step B was added all at once and the reaction mixture was refluxed overnight. The cooled mixture was poured into water and the aqueous phase was extracted three times with ethyl acetate. The organic extracts were dried with brine and magnesium sulfate and evaporated to give a red oil which was taken up in methanol and crystallized to give the title compound, 2.97 g (77%), m.p. 245 - 246°C.

D. 4-(2-Chlorobenzoyl)-3-ethoxy-5-phthalimido-1-(2,4,6-trichlorophenyl)pyrazole.

A solution of 0.55 g (1.0 mmol) of the compound of Step C in 10 mL of dry dimethyl sulfoxide was treated portionwise with 36 mg (1.5 mmol) of sodium hydride and the resulting mixture was stirred for 30 minutes at room temperature. Then 0.21 mL (0.25 g, 1.61 mmol) of diethyl sulfate was added and the reaction mixture was stirred for one hour at room temperature. The reaction mixture was poured into water and the product was extracted into ethyl acetate. The extracts were washed with water and dried with brine and magnesium sulfate, and evaporated to a gum. The product was crystallized from boiling ethanol to give the product (230 mg, 40%) as fine crystals, m.p. 215 - 216°C.

E. 5-Amino-4-(2-chlorobenzoyl)-3-ethoxy-1-(2,4,6-trichlorophenyl)pyrazole.

A suspension of 184 mg of the compound of Step D in 10 mL of ethanol was treated with 0.5 mL of 55% hydrazine hydrate. The reaction mixture was stirred for 30 minutes at room temperature, cooled, and the solids were filtered off and dried. The filtrate was concentrated to a gum which was triturated with ether and filtered. The solids were dried to give 104 mg of the title compound. Anal. Calcd. for $C_{18}H_{13}O_2N_3Cl_4$: C, 48.57; H, 2.94; N, 9.43.



Example 85-Dimethylamino-4-(2-chlorobenzoyl)-3-methoxy-1-(2,4,6-trichlorophenyl)pyrazole.

A solution of 60 mg (0.14 mmol) of 5-amino-4-(2-chlorobenzoyl)-3-methoxy-1-(2,4,6-trichlorophenyl) pyrazole prepared according to Example 7 in 5 mL of dry dimethyl sulfoxide was treated with 22 mg (0.88 mmol) of oil-free sodium hydride to give a yellow solution. After 1 hour at room temperature, 0.2 mL (0.46 g, 3.21 mmol) of methyl iodide was added. After stirring for 5 hours, the reaction mixture was poured into water and the product was extracted into ethyl acetate. After drying with brine and magnesium sulfate, the solvent was removed to give the title product as a one-spot foam. ¹H-NMR (CDCl₃): 2.77 (6H, s), 3.63 (3H, s), 7.24 - 7.42 (4H, m), 7.48 (2H, s).

Example 9A. 3,3-Bis-ethoxy-2-(3-trifluoromethylbenzoyl)-acrylonitrile.

Sodium (0.126 g, 5.5 mmol) was dissolved in 15 mL of ethanol and 20 mL of dioxane was added followed by 1.59 g (5.0 mmol) of 3,3-bis-methylthio-2-(3-trifluoromethylbenzoyl)-acrylonitrile and the reaction mixture was refluxed for 4 hours and let stir overnight at room temperature. This compound was relatively unstable to aqueous conditions and was not isolated as such. Instead, an aliquot of the mixture was stripped and the product was identified by 300 MHz proton NMR: NMR (DMSO-d₆): 1.14 (6H, t, J = 7), 3.45 (4H, q, J = 7), 7.44 - 8.16 (4H, m).

20 B. 5-Amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-ethoxy-4-(3-trifluoromethylbenzoyl)pyrazole.

An aliquot of the above solution of step A containing approximately two millimoles of 3,3-bis-ethoxy-2-(3-trifluoromethylbenzoyl)acrylonitrile was reacted with 0.49 g (2.0 mmol) of 2,6-dichloro-4-trifluoromethylphenylhydrazine in 10 mL of ethanol under reflux overnight. The cooled mixture was poured into dilute hydrogen chloride (HCl) and the product was extracted into ethyl acetate (EtOAc), washed with water and brine, and dried over magnesium sulfate (MgSO₄). Chromatography on silica gel with 4:1 hexane/EtOAc gave the title product, 320 mg (31%), m.p. 77 - 78°C from pentane.

Example 10

30 5-Amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(2,5-dimethylbenzoyl)-3-ethoxypyrazole.

A solution of 0.26 g (1.5 mmol) of 2,5-dimethylbenzoylacetonitrile, 0.34 mL (0.31 g, 1.60 mmol) of tetraethylorthocarbonate and 0.30 mL (0.33 g, 3.20 mmol) of acetic

anhydride in 10 mL of EtOAc was refluxed overnight. The solvent was evaporated and 10 mL of absolute ethanol was added and then stripped. The residues were dissolved in 10 mL of ethanol, 368 mg (1.5 mmol) of 2,6-dichloro-4-trifluoromethylphenylhydrazine and 0.7 mL (0.51 g, 5.0 mmol) of triethylamine were added, and the mixture
5 was refluxed for 90 minutes. The mixture was poured into water, extracted with EtOAc and the organic extracts were washed with dilute HCl and brine, and dried over MgSO₄. Evaporation gave a gum which was chromatographed on silica gel with 4:1 hexane/EtOAc to give the title product which crystallized from pentane, 15 mg (2%), m.p. 99 - 101°C.

10

Example 111-(2,6-Dichloro-4-trifluoromethylphenyl)-5-methyl-4-(3-methylbenzoyl)-3-methylthiopyrazole.

A solution of 2.97 g (16.9 mmol) of 4-(3-methylphenyl)butane-2,4-dione and 4.04 mL (5.14 g, 67.6 mmol) of carbon disulfide in 60 mL of dry dimethyl sulfoxide was
15 treated portionwise with 0.89 g (37.1 mmol) of oil-free sodium hydride at 15 - 18°C. After stirring 30 minutes, 2.31 mL (5.27 g, 37.1 mmol) of methyl iodide was added dropwise and the reaction mixture was allowed to stir at room temperature for 1 hour. It was then poured into water and the product was extracted into ether, backwashed with water and dried over MgSO₄ to give 4.30 g (91%) of an oil which crystallized in the
20 refrigerator overnight, m.p. 44 - 46°C. ¹H-NMR (CDCl₃): 2.16 (3H, s), 2.38 (6H, s), 2.72 (3H, s), 7.26 - 7.38 (2H, m), 7.58 - 7.74 (2H, m). A mixture of 1.95 g (6.96 mmol) of 3,3-bismethylthio-2-(3-methylbenzoyl)-2-acetylene and 1.71 g of 2,6-dichloro-4-trifluoromethylphenylhydrazine in 20 mL of ethanol was refluxed for 6 hours and then stirred at room temperature for 48 hours. The reaction mixture was poured into dilute
25 HCl solution and the product was extracted into EtOAc. The solution was dried and concentrated and the residues were chromatographed on silica gel with 10:1 hexane/EtOAc to give the title product which crystallized from pentane, 1.67 g (52%), m.p. 103 - 104°C.

Example 12

30

5-Amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(5-[3-hydroxypropyl]-2-methylbenzoyl)-3-methylthiopyrazole.

A solution of 0.530 g (1.0 mmol) of 5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(5-[β-methylcarbonylthyl]-2-methylbenzoyl)-3-

methylthiopyrazole in 10 mL of THF was cooled in an ice bath while 1.33 mL of a 1.5 M solution of DIBAL in THF was added. The reaction mixture was warmed to room temperature and then quenched with water. The product was extracted into EtOAc, dried and concentrated. The residues were chromatographed on silica gel using mixtures of hexane/EtOAc to elute the title product which was isolated as an amorphous foam, 174 mg (34%). Anal. Calcd. for $C_{22}H_{20}O_2N_3SCl_2F_3$: C, 50.97; H, 3.88; N, 8.10. Found, C, 51.10; H, 3.96; N, 7.60.

Example 13

[5-Amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methylsulfonyl-1H-pyrazol-4-yl]-(2,5-dimethylphenyl)methanone.

To a solution of 200 mg (0.42 mmol) of [5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methylsulfonyl-1H-pyrazol-4-yl]-(2,5-dimethylphenyl)methanone in 10 mL of THF was added 0.176 g (2.10 mmol) of anhydrous sodium bicarbonate followed by a solution of 145 mg (0.42 mmol) of 3-chloroperoxybenzoic acid in 8 mL of THF. After two hours at room temperature, 0.5 g of sodium bicarbonate and an additional 290 mg (0.84 mmol) of 3-chloroperoxybenzoic acid was added. The reaction mixture was heated briefly to 50°C, let cool and stirred overnight at room temperature. The reaction mixture was added to water and the product was extracted into ethyl acetate. The organic extracts were washed with dilute sodium bicarbonate solution and then dried and evaporated. The title compound was crystallized from ether to give 150 mg (70% yield) of colorless crystals, m.p. 193.5 - 194.5°C

Example 14


The following compounds in Tables 1 and 2 were prepared according to the indicated Example.

TABLE 1

5

10

15



R_1	R_2	R_{13}	R_{14}	R_{15}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
amino	SCH_3	2-Cl	4-Cl	6-Cl	2-Cl	H	m.p. 178-180	1
amino	SCH_3	2-Cl	4-Cl	6-Cl	H	H	m.p. 178-180	1
amino	SCH_3	4- CF_3	H	H	2-Cl	H	m.p. 150-153	1
amino	SCH_3	2-Cl	4-Cl	6-Cl	2-F	H	m.p. 204-206	1
NHCH_3	SCH_3	2-Cl	4-Cl	6-Cl	2-Cl	H	m.p. 135-137	2
$\text{N}(\text{CH}_3)_2$	SCH_3	2-Cl	4-Cl	6-Cl	2-Cl	H	m.p. 194-197	2
$\text{N}(\text{CH}_3)_2$	CH_3	2-Cl	4-Cl	6-Cl	2-Cl	H	m.p. 220-222	6
amino	SCH_3	2- CF_3	H	H	2-Cl	H	m.p. 186-188	1
amino	SCH_3	2-Cl	4-Cl	6-Cl	2-cyclopropyl	H	m.p. 165-167	1
amino	SCH_3	2-Cl	4-Cl	6-Cl	4- CH_3	H	m.p. 230-232	1
amino	SCH_3	2-Cl	4-Cl	6-Cl	2-Cl	4-Cl	m.p. Amorphous. Anal. Calc'd for $\text{C}_{17}\text{H}_{10}\text{N}_3\text{O}_2\text{Cl}_5$: C, 42.39; H, 2.09; N, 8.72. Found: C, 41.94; H, 2.06; N, 8.07.	1
$\text{N}(\text{CH}_3)_2$	CH_3	2-Cl	4-Cl	6-Cl	2-Cl	H	m.p. 108-109	6
NH_2	SCH_3	2-F	4-F	6-F	2-Cl	H	m.p. 156-158	1

5

10

15

20

R_1	R_2	R_{13}	R_{14}	R_{15}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
5 $N(CH_3)_2$	SCH_3	2-Cl	4-Cl	6-Cl	2-F	H	m.p. Amorphous. HRMS for $C_{19}H_{16}N_3O_3SCl_3F$ Calc'd: 466.9984 Found: 466.9990	2
	SCH_3	2-Cl	6-Cl	H	2-F	H	m.p. 182-184	1
	SCH_3	2-F	4-F	H	2-Cl	H	m.p. 147-150	1
10 $N(CH_3)_2$	SCH_3	2-Cl	4-Cl	6-Cl	3-Cl	H	m.p. 121-125	2
	$NHCH_3$	2-Cl	4-Cl	6-Cl	2-Cl	H	m.p. 86-90	
	SCH_3	2-Cl	4-Cl	6-Cl	2-OCH ₃	H	m.p. 200-202	1
15 $NH(CH_2)_3OC_6H_5$	SCH_3	2-Cl	6-Cl	4-CF ₃	2-Cl	H	m.p. 207-210	1
	SCH_3	2-Cl	6-Cl	4-Cl	2-Cl	H	m.p. Amorphous. Anal. Calcd. for $C_{26}H_{21}N_3O_2SCl_4$: C, 53.71; H, 3.64; N, 7.22. Found: C, 53.67; H, 3.41; N, 7.46.	5
	SCH_3	2-Cl	6-Cl	4-Cl	3-CH ₃	H	m.p. 178-180	1
20 NH_2	SCH_3	2-Cl	6-Cl	4-Cl	3-Cl	H	m.p. 149-151	1
	SCH_3	2-Cl	6-Cl	4-CF ₃	3-CH ₃	H	m.p. 150-153	1
	SCH_3	2-Cl	6-Cl	4-CF ₃	3-CH ₃	H		1

R_1	R_2	R_{13}	R_{14}	R_{15}	R_{11}	R_{12}	Physical Data (m.p. In °C)	Process of Example
5 $N(CH_3)_2$ NH_2 $NHCH_2COOH$	SCH_3	2-Cl	6-Cl	4- CF_3	3-Cl	H	m.p. 120-122	2
	SCH_3	2-Cl	6-Cl	4-Cl	3- CF_3	H	m.p. 158-160	1
	SCH_3	2-Cl	6-Cl	4-Cl	2-Cl	H	m.p. > 250 HRMS for $C_{19}H_{13}N_3O_3SCl_4$: Calcd: 525.9930 Found: 525.9348	1
10 NH_2	SCH_3	2-Cl	6- CF_3	4-Cl	3- CF_3	H	m.p. Amorphous. Anal. Calcd. for $C_{19}H_{11}N_3O_3SCl_2F_6$: C, 44.30; H, 2.15; N, 8.15. Found: C, 44.51; H, 2.29; N, 7.98	1
	SCH_3	2- CH_3	4-Cl	H	2-Cl	H	m.p. 125-129	1
	SCH_3	2- CH_3	4-Cl	H	3-Cl	H	m.p. 112-115	1
15 NH_2 NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	2- CH_3	6- CH_3	m.p. 130-132	1
	SCH_3	2- CH_3	6- CH_3	H	3-Cl	H	m.p. 148-151	1
20								

R_1	R_2	R_{13}	R_{14}	R_{15}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
5 $N(CH_3)_2$	SCH_3	2-Cl	4- CF_3	6-Cl	3- CF_3	H	m.p. Amorphous. Anal. Calcd. for C ₂₁ H ₁₅ N ₃ O ₃ Cl ₂ F ₆ : C, 46.50; H, 2.78; N, 7.74. Found: C, 46.75; H, 2.93; N, 7.58	2
	NH_2	2-Cl	4- CF_3	H	3-Cl	H	m.p. 124-127	1
	NH_2	2- CH_3	6- CH_3	H	3-Cl	H	m.p. 139-142	1
	NH_2	2-Cl	4-Cl	6-Cl	2- CH_3	5- CH_3	m.p. 182-184	1
10 CH_3	SCH_3	2-Cl	4-Cl	6-Cl	3- CH_3	H	m.p. 116-117	
	NH_2	2- CH_3	4-Cl	6- CH_3	3- CF_3	H	m.p. Amorphous. Anal. Calcd. for C ₂₀ H ₁₇ N ₃ O ₃ ClF ₃ : C, 54.48; H, 3.88; N, 9.53. Found: C, 54.60; H, 3.91; N, 9.08	1
	NH_2	2- CH_3	4-Cl	6- CH_3	3- CF_3	H		

R ₁	R ₂	R ₁₃	R ₁₄	R ₁₅	R ₁₁	R ₁₂	Physical Data (m.p. in °C)	Process of Example
NH ₂	SCH ₃	2-CH ₃	4-Cl	6-CH ₃	3-Cl	H	m.p. Amorphous. Anal. Calcd. for C ₁₉ H ₁₇ N ₃ O ₃ SCl ₂ : C, 56.16; H, 4.21; N, 10.34. Found: C, 55.93; H, 4.21; N, 10.01	1
NH ₂	SCH ₃	2-CH ₃	4-CH ₃	6-CH ₃	3-Cl	H	m.p. 163-165	1
NH ₂	SCH ₃	2-CH ₃	4-CH ₃	6-CH ₃	3-CH ₃	H	m.p. 124-127	1
NH ₂	SCH ₃	2-CH ₃	4-CH ₃	6-CH ₃	3-CF ₃	H	m.p. 143-146	1
NH ₂	SCH ₃	2-CH ₃	4-Br	6-CH ₃	3-CF ₃	H	m.p. Amorphous. Anal. Calcd. for C ₂₀ H ₁₇ N ₃ O ₃ SB ₂ F ₃ : C, 49.59; H, 3.53; N, 8.67. Found: C, 49.45; H, 3.49; N, 8.37	1
NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-CH ₃	3-CH ₃	m.p. 196-198	1

5

10

15

20

	R ₁	R ₂	R ₁₃	R ₁₄	R ₁₆	R ₁₁	R ₁₂	Physical Data (m.p. in °C)	Process of Example
5	NH ₂	SCH ₃	2-CH ₃	4-Br	6-CH ₃	3-Cl	H	m.p. Amorphous. Anal. Calcd. for C ₁₉ H ₁₇ N ₃ O ₃ BrCl: C, 50.63; H, 3.80; N, 9.32. Found: C, 50.40; H, 3.77; N, 8.94	1
10	NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-CH ₃	5-(CH ₂) ₃ - CO ₂ CH ₃	m.p. Amorphous. Anal. Calcd. for C ₂₄ H ₂₂ N ₃ O ₃ Cl ₂ F ₃ : C, 51.43; H, 3.96; N, 7.50. Found: C, 51.59; H, 4.10; N, 7.17	1
15	NH ₂	SCH ₃	2-CH ₃	6-CH ₃	4-Br	2-CH ₃	5-CH ₃	m.p. Amorphous. Anal. Calcd. for C ₂₁ H ₂₂ N ₃ O ₃ : C, 56.76; H, 4.99; N, 9.45. Found: C, 56.37; H, 5.01; N, 9.04	1
20	NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-OCH ₃	H	m.p. 172-174	1

R ₁	R ₂	R ₁₃	R ₁₄	R ₁₅	R ₁₁	R ₁₂	Physical Data (m.p. in °C)	Process of Example
NH ₂	OCH ₃	2-Cl	4-Cl	6-Cl	2-Cl	H	m.p. Amorphous. ¹ H-NMR(CDCl ₃): 3.68 (3H, s), 5.86(2H, broad s), 7.26- 7.44(4H, m) 7.51(2H, s).	7
NH ₂	OCH ₂ CH ₃	2-Cl	4-Cl	6-Cl	2-Cl	H	m.p. Amorphous. Anal. Calcd. for C ₁₈ H ₁₃ N ₃ O ₂ Cl ₄ : C, 48.57; H, 2.94; N, 9.44. Found: C, 48.41; H, 2.52; N, 9.43	7
N(CH ₃) ₂	OCH ₃	2-Cl	4-Cl	6-Cl	2-Cl	H	m.p. Amorphous. HRMS for C ₁₉ H ₁₅ N ₃ O ₂ Cl ₄ : Calcd: 456.9913 Found: 456.9960	8
NH ₂	OCH ₂ CH ₃	2-Cl	4-CF ₃	6-Cl	3-CF ₃	5-CF ₃	m.p. Amorphous. Anal. Calcd. for C ₂₀ H ₁₀ N ₃ O ₂ Cl ₂ F ₉ : C, 41.25; H, 1.73; N, 7.21. Found: C, 41.49; H, 2.01; N, 7.01	1

5

10

15

20

R_1	R_2	R_{13}	R_{14}	R_{16}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
NH_2	OCH_2CH_3	2-Cl	4- CF_3	6-Cl	2- CH_3	5- CH_3	m.p. Amorphous. High Resolution Mass Spectrum Calcd. for $C_{22}H_{20}N_3OCl_2F_3$: 472.0806. Found, 472.0817	1
NH_2	CH_2CH_2- CH_3	2-Cl	4- CF_3	6-Cl	2- CH_3	5- CH_3	m.p. Amorphous. High Resolution Mass Spectrum Calcd. for $C_{21}H_{20}N_3OC_1_2F_3$: 469.0935. Found: 469.0889	6
NH_2	CH_2CH_2- CH_3	2-Cl	4-Cl	6-Cl	2- CH_3	5- CH_3	m.p. Amorphous. High Resolution Mass Spectrum Calcd. for $C_{22}H_{20}N_3OCl_2F_3$: 436.0761. Found: 436.0764	6

5

10

15

20

R ₁	R ₂	R ₁₃	R ₁₄	R ₁₅	R ₁₁	R ₁₂	Physical Data (m.p. in °C)	Process of Exempl
NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	3-OCH ₃	H	m.p. Amorphous. ¹ H-NMR(CDCl ₃) δ 2.38(3H, s), 3.90(3H, s), 5.79(2H, broad s), 7.07(1H, d, J=7), 7.16(1H, s), 7.23(1H, d, J=7), 7.39(1H, t, J=7), 7.79(2H, s)	3
NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-CH ₃	5-(CH ₂) ₄ OH	m.p. Amorphous. High Resolution Mass Spectrum Calcd. for C ₂₃ H ₂₂ N ₃ O ₂ SCl ₂ F ₃ : 532.0840. Found: 532.0871	12
NH ₂	CH ₂ CH ₃	2-Cl	4-CF ₃	6-Cl	2-CH ₃	5-CH ₃	m.p. Amorphous. Anal. Calcd. for C ₂₁ H ₁₈ N ₃ OCl ₂ F ₃ : C, 55.29; H, 3.97; N, 8.21. Found: C, 55.62; H, 4.35; N, 8.16	6

R_1	R_2	R_{13}	R_{14}	R_{15}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
NH_2	CH_2CH_3	2-Cl	4-Cl	6-Cl	2- CH_3	5- CH_3	m.p. Amorphous. Anal. Calcd. for $C_{20}H_{18}N_3OCl_3$: C, 56.81; H, 4.29; N, 9.94. Found: C, 56.88; H, 4.09; N, 9.62	6
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	2- CF_3	5- CF_3	m.p. Amorphous. Anal. Calcd. for $C_{20}H_{20}N_3O_3SCl_2F_9$: C, 41.25; H, 1.71; N, 7.21. Found: C, 41.20; H, 1.87; N, 6.89	1
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	2- CH_3	5- CH_2CO_2 - C_2H_5	m.p. Amorphous. Anal. Calcd. for $C_{23}H_{20}N_3O_3SCl_2F_3$: C, 50.55; H, 3.68; N, 7.69. Found: C, 50.50; H, 3.50; N, 7.29	1

5

10

15

20

R ₁	R ₂	R ₁₃	R ₁₄	R ₁₅	R ₁₁	R ₁₂	Physical Data (m.p. In °C)	Process of Example
NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-CH ₃	5-(CH ₂) ₂ OH	m.p. Amorphous. HRMS for C ₂₁ H ₁₈ N ₃ O ₂ SCl ₂ F ₃ Calcd: 503.0646 Found: 503.0147	12
NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-OCH ₃	5-OCH ₃	m.p. Amorphous. 'H-NMR(CDCl ₃) δ 2.30(3H, s), 3.60(6H, s), 5.85(2H, broad s), 6.80- 6.96(3H, m), 7.74(2H, s).	1
NH ₂	OCH ₂ CH ₃	2-Cl	4-CF ₃	6-Cl	3-CF ₃	H	m.p. 112-114	9
NH ₂	OCH ₂ CH ₃	2-Cl	4-CF ₃	6-Cl	3-CF ₃	H	m.p. 77-78	9
NH ₂	OCH ₂ CH ₃	2-Cl	4-CF ₃	6-Cl	3-CH ₃	H	m.p. 103-104	9
NH ₂	OCH ₂ CH ₃	2-CH ₃	4-Br	6-CH ₃	3-CF ₃	H	m.p. 158-160	9
NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-CH ₃	5-Isopropyl	m.p. Amorphous. Anal. Calcd. for C ₂₂ H ₂₀ N ₃ O ₂ SCl ₂ F ₃ : C, 52.59; H, 3.98; N, 8.36. Found: C, 52.39; H, 4.01; N, 8.08	1

5

10

15

20

R_1	R_2	R_{13}	R_{14}	R_{15}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	2- CH_3	5- $(CH_2)_3OH$	m.p. Amorphous. Anal. Calcd. for $C_{22}H_{20}N_3O_2SCl_2F_3$: C, 50.97; H, 3.88; N, 8.10. Found: C, 51.10; H, 3.96; N, 7.60	12
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	2- $COOC_2H_5$	H	m.p. 211-216	1
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	R_{11} and R_{12} with the phenyl to which they are attached form 1- naphthyl	H	m.p. 115-118	1
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	3-Br	H	m.p. Amorphous. Calcd. for $C_{18}H_{11}N_3OSBrCl_2F_3$ C 41.16, H 2.11, N 8.00. Found C 41.37, H 1.92, N 7.85.	1
NH_2	SCH_3	2-Cl	4- $SO_2^-NH_2$	6-Cl	3- CF_3	H	m.p. 272-274	1

5

10

15

20

R_1	R_2	R_{13}	R_{14}	R_{15}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	3- SO_2NH_2	H	m.p. 99-100	1
NH_2	SCH_3	2- CH_3	4-Br	6- CH_3	3- SO_2NH_2	H	m.p. 242-244	1
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	3- $SO_2N(CH_3)_2$	H	m.p. Amorphous. Anal. Calcd. for C ₂₀ H ₁₇ N ₄ O ₃ S ₂ Cl ₂ F 3/1/4C ₄ H ₁₀ O: C, 44.10; H, 3.44; N, 9.80. Found: C, 43.88; H, 3.29; N, 9.68	1
NH_2	SCH_3	2- CH_3	4-Br	6- CH_3	3- $SO_2N(CH_3)_2$	H	m.p. Amorphous. Anal. Calcd. for C ₂₁ H ₂₃ N ₄ O ₃ S ₂ Br: C, 48.18; H, 4.43; N, 10.70. Found: C, 48.42; H, 4.24; N, 10.52	1
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	3- $SO_2N(CH_3)_2$	H	m.p. 192-194	1
NH_2	SCH_3	2-Cl	4-Cl	6-Cl	2-(2-thienyl)	H	m.p. 171.5-172.5	1
NH_2	SCH_3	2-Cl	6-Cl	4- CF_3	H	H	m.p. 192-194	1
NH_2	CH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5- CH_3	m.p. 175-176	6
NH_2	CH_3	2- CH_3	6- CH_3	4-Br	2- CH_3	5- CH_3	m.p. 158-160	6

5

10

15

20

R_1	R_2	R_{13}	R_{14}	R_{15}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
NH_2	SCH_3	2-Cl	6-Cl	4- CF_3	3-N(CH_3) ₂	H	HRMS for $C_{20}H_{17}ON_4SCl_2F_3$ Calcd: 488.0452 Found: 488.0408	1
$NH(C_3H_7)$	SCH_3	2-Cl	6-Cl	4-Cl	2-Cl	H	Calcd. C, 49.10; H, 3.50; N, 8.54; Found: C, 50.37; H, 3.28; N, 8.47.	5
NH_2	SO_2CH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5- CH_3	m.p. 193.5-194.5	13
NH_2	SCH_3	2-Cl	6-Cl	4- CF_3	3-phenyl	H	m.p. 124-127	1
NH_2	SCH_3	2-Cl	6-Cl	4- CF_3	2-pyrrolyl	H	HRMS Calcd. 510.0295 Found 510.0455	1
$N(CH_3)(C_2H_5)$	SCH_3	2-Cl	6-Cl	4-Cl	2-Cl	H	FAB Mass Spectrum: 490	5
NH_2	SCH_3	2-Cl	6-Cl	4-Cl	2- CH_3	5- i -Pr	HRMS Calcd. 467.0393 Found 467.0395	1
NH_2	SCH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5-n-butyl	HRMS Calcd. 515.0809 Found 515.0892	1

5

10

15

20

R_1	R_2	R_{13}	R_{14}	R_{16}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
$N(C_2H_5)_2$	SCH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5-IPr	HRMS Calcd. 557.1277 Found 557.1287	5
NH_2	CH_3	2-Cl	6-Cl	4-Cl	2- CH_3	5-IPr	HRMS Calcd. 435.0669 Found 435.0682	1
$N(C_2H_5)(C_3H_7)$	SCH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5-IPr	MS parent 571, 529, 494, 360, 160 (100%)	5
$N(C_2H_5)(sec\text{-}butyl)$	SCH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5-IPr	HRMS Calcd. 585.1589 Found 585.1500	5
$N(CH_3)(C_2H_5)$	SCH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5-IPr	HRMS Calcd. 543.1121 Found 543.1166	5
$N(C_2H_5)(C_3H_7)$	SCH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5-IPr	HRMS Calcd. 569.1277 Found 569.1433	5
NH_2	SCH_3	2-Cl	6-Cl	4- CF_3	2-n-propyl	5- CH_3	HRMS Calcd. 501.0653 Found 501.0551	1

5

10

15

20

R_1	R_2	R_{13}	R_{14}	R_{15}	R_{11}	R_{12}	Physical Data (m.p. in °C)	Process of Example
NH_2	SCH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5-n-propyl	HRMS Calcd. 501.0653 Found 501.0698	1
$N(CH_3)(C_2H_5)$	SCH_3	2-Cl	6-Cl	4- CF_3	2- CH_3	5-IPr	HRMS Calcd. 555.1121 Found 555.0756	5
NH_2	SCH_3	2-Cl	4-Cl	6-Cl	2- CH_3	6- CH_3	HRMS Calcd. 439.0080 Found 439.0097	1
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	2-Cl	6-Cl	m.p. 212-213	1
NH_2	SCH_3	2- CH_3	4-Br	6- CH_3	2-Cl	6-Cl	m.p. 252-254	1
NH_2	SCH_3	2-Cl	4-Cl	6-Cl	2-Cl	6-Cl	m.p. 237-239	1
NH_2	SCH_3	2-Cl	4-Cl	6-Cl	2- OCH_3	H	m.p. 168-171	1
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	2-OIPr	6-Cl	MS 537 (parent ion) 480, 341 (100%), 308, 255, 155	1
NH_2	SCH_3	2- CH_3	4-Br	6- CH_3	2- OCH_3	6-Br	m.p. 191-193	1
NH_2	SCH_3	2-Cl	4- CF_3	6-Cl	2- OCH_3	6-Br	m.p. 192-194	1
NH_2	SCH_3	2-Cl	4-Cl	6-Cl	2- OCH_3	6-Br	m.p. 218-220	1
NH_2	SCH_3	2-Cl	4-Cl	6-Cl	2-Br	5-Br	m.p. 229-231	1

5

10

15

20

R ₁	R ₂	R ₁₃	R ₁₄	R ₁₅	R ₁₁	R ₁₂	Physical Data (m.p. in °C)	Process of Example
NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-Br	6-Br	m.p. 172-174	1
NH ₂	SCH ₃	2-CH ₃	4-Br	6-CH ₃	2-Br	5-Br	m.p. 179-181	1
NH ₂	SCH ₃	2-CH ₃	4-CH ₃	6-CH ₃	2-Br	5-Br	m.p. 195-197	1
NH ₂	SCH ₃	2-CH ₃	4-Br	6-CH ₃	2-CH ₃	5-NO ₂	m.p. 118-119	1
NH ₂	SCH ₃	2-Cl	4-Cl	6-Cl	2-C ₂ H ₅	H	m.p. 146-150	1
NH ₂	SCH ₃	2-Cl	4-Cl	6-Cl	2-CF ₃	H	m.p. 175-177	1
NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-Cl	5-NO ₂	m.p. 98.0-98.5	1
NH ₂	SCH ₃	2-CH ₃	4-Br	6-CH ₃	2-Cl	5-NO ₂	m.p. 116-118	1
NH ₂	SCH ₃	2-Cl	4-CF ₃	6-Cl	2-CH ₃	5-NO ₂	m.p. 99-100	1
NH ₂	SCH ₃	2-CH ₃	4-CH ₃	6-CH ₃	2-CH ₃	5-NO ₂	m.p. 193-195	1
NH ₂	SCH ₃	2-Cl	4-Cl	6-Cl	2-OC ₃ H ₇	H	¹ H-NMR (CDCl ₃) δ 0.87 (3H, t, J=7), 1.68 (2H, m), 2.32 (3H, s), 3.96 (2H, q, J=7), 5.80 (1H, broad s), 6.93 (1H, d, J=7), 7.03 (1H, t, J=7), 7.27 (1H, d, J=7), 7.42 (1H, t, J=7), 7.52 (2H, s)	1

5


10

15

20

-48-

TABLE 2



	R ₃	R ₄	Phys. Data (m.p. in °C)	Process of Example
15	C ₂ H ₅ CHC ₄ H ₉	2,6-Cl ₂ -4-CF ₃ Ph	HRMS Calcd. 467.0809. Found 467.0913.	1
	C ₃ H ₇ CH=CH-C ₂ H ₅	2,6-Cl ₂ -4-CF ₃ Ph	FAB Mass Spectrum: 466	1
20	2-methylcyclopentyl	2,4,6-Cl ₃ Ph	HRMS Calcd. 417.0236. Found 417.0328.	1
	2-OC ₂ H ₅ -1-naphthyl	2,6-Cl ₂ -4-CF ₃ Ph	m.p. 149-151	1
	2-OC ₂ H ₅ -1-naphthyl	2,4,6-Cl ₃ Ph	m.p. 125-128	1
25	3-CF ₃ -Ph	1,3-(CH ₃) ₂ -4-NO ₂ - pyrazol-5-yl	Calcd. for C ₁₇ H ₁₅ O ₃ N ₆ SF ₃ : C, 46.36; H, 3.43; N, 19.08. Found: C, 46.51; H, 3.37; N, 18.10.	1

-49-

5

Example 15A. 3-Trifluoromethylphenylthioacetonitrile.

To sodium (0.62 g, 27.0 mmol) dissolved in 40 mL of ethanol was added 4.79 g (26.9 mmol) of 3-trifluoromethylthiophenol and 2.04 g (27.0 mmol) of chloroacetonitrile. The reaction mixture was heated at reflux for 1 hour and then
10 stirred overnight at room temperature. To the cooled reaction mixture was added one volume of ether and the precipitated solids were removed by filtration. The filtrate was evaporated on the rotary evaporator to give the product as an oil in essentially quantitative yield. This material was used in the following reaction without further purification.

15

B. 3-Trifluoromethylphenylcyanomethylsulfoxide.

A solution of 3.00 g (13.8 mmol) of 3-trifluoromethylphenylthioacetonitrile in 130 mL of methylene chloride was cooled to 5°C under dry N₂ and treated with 4.89 g (28.35 mmol) of m-chloroperbenzoic acid. The reaction mixture was stirred for 48 hours at room temperature and then cooled in ice, after which the insolubles were
20 removed by filtration. The filtrate was washed with 10% sodium sulfate solution until all traces of peroxides had been removed and then dried over magnesium sulfate and evaporated to a pale yellow oil which was used in the subsequent reaction without further purification.

C. 3,3-Bis-methylthio-2-(3-trifluoromethylphenylsulfonyl)acrylonitrile.

25

A solution of 13.82 mmol (crude product) of 3-trifluoromethylphenylcyanomethylsulfoxide in 30 mL of dry dimethylsulfoxide and 1.25 mL (1.58 g, 20.7 mmol) of CS₂ was cooled to about 15°C in an ice bath under dry nitrogen. Then 0.99 g (41.5 mmol) of oil-free sodium hydride was added portionwise below 20°C and the deep red solution was let stir at room temperature for 75
30 minutes. The reaction mixture was cooled to 15°C, quenched with 2.58 mL (5.89 g, 41.5 mmol) of methyl iodide and let stir overnight at room temperature. The reaction mixture was poured into ice/water and let granulate for 3.5 hours. The product was filtered and air dried to give 3.51 g (72%) of the product. The analytical sample was crystallized from EtOH/H₂O, m.p. 109-110°C.

35

-50-

D. 5-Amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(3-trifluoromethylbenzenesulfonyl)-3-methylthiopyrazole.

5 A suspension of 0.50 g (1.42 mmol) of 3,3-bis-methylthio-2-(3-trifluoromethylphenylsulfonyl)acrylonitrile and 0.35 g (1.42 mmol) of 2,6-dichloro-4-trifluoromethylphenylhydrazine in 10 mL of ethanol was heated at reflux for 2.5 hours, solution occurring as the reaction mixture was warmed. The mixture was stirred overnight at room temperature and was then poured into cold water. The product
10 was extracted into ethyl acetate and the extracts were dried with magnesium sulfate and evaporated. The residues were crystallized from ether, and the product was filtered off and air dried to give 314 mg (40%) of the desired product, m.p. 201 - 203°C. Anal. Calcd. for $C_{18}H_{11}O_2N_3S_2Cl_2F_6$: C, 39.28; H, 2.02; N, 7.64. Found: C, 39.35; H, 2.19; N, 7.48.


15 E. 5-Dimethylamino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(benzenesulfonyl)-3-methylthiopyrazole.

A solution of 0.241 g (0.5 mmol) of 5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(benzenesulfonyl)-3-methylthiopyrazole in 5 mL of dry dimethylsulfoxide was treated with 36 mg (1.5 mmol) of oil-free sodium hydride under
20 dry nitrogen in a flame-dried flask at room temperature. After 30 minutes, a clear, pale yellow solution had formed. This solution was treated with 0.5 mL (8.0 mmol) of methyl iodide and stirred for 1 hour. Then the reaction mixture was poured into water and extracted twice with ethyl acetate. The combined extracts were dried with brine and with magnesium sulfate and evaporated. The residues crystallized from ether to
25 give the desired product in 81% yield, m.p. 163 - 164°C.

Example 16

The following compounds were prepared in accordance with Example 15.

-51-



15

20

25

R ₁₁	R ₁₃ , R ₁₄ , R ₁₅	R ₁	M.P. (°C) or Analysis
H	2,4,6-trichloro	NH ₂	161-162
H	2,4,6-trichloro	N(CH ₃) ₂	200-202
2-(i-propyl)	2,4,6-trichloro	NH ₂	180-182
2-OCH ₃	2,4,6-trichloro	NH ₂	212-215
2-Cl	2,4,6-trichloro	NH ₂	Anal. Calcd. for C ₁₆ H ₁₁ O ₂ N ₃ S ₂ Cl ₄ : C, 39.60; H, 2.39; N, 8.33. Found: C, 39.76; H, 2.29; N, 8.69
H	2,6-Cl ₂ -4-CF ₃	NH ₂	209.5-210.5
H	2,6-Cl ₂ -4-CF ₃	N(CH ₃) ₂	163-164
3-CF ₃	2,6-Cl ₂ -4-CF ₃	NH ₂	201-203
3-CF ₃	2,6-Cl ₂ -4-CF ₃	N(CH ₃) ₂	137-138

30

Example 17

4-(2-Chlorophenyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methylthiopyrazolo[3,4-d]pyrimidine.

A suspension of 669 mg (1.39 mmol) of 5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(2-chlorobenzoyl)-3-methylthiopyrazole in 5 mL of formamide was heated at 150°C overnight. A pale yellow solid precipitated upon cooling of the

35

-52-


reaction mixture. A total of 50 mL of water was added to the stirred suspension to
 5 complete the precipitation of the product which was filtered off and washed with water.
 An inseparable trace of starting material was observed in the product by thin layer
 chromatography (TLC) and so the above procedure was repeated on the mixture
 giving a brown solid containing no trace of starting material. Trituration of this solid
 with methylene chloride gave a pale yellow solution which was concentrated to give
 10 the desired product as a white crystalline solid, m.p. 156-158°C.

Example 18

The following compounds were prepared in accordance with Example 17.

15

20



25

30

35

R ₃	R ₉	R ₁₃	m.p.(°C) or HRMS
2-Cl-Ph	H	Cl	193-195
3-Cl-Ph	H	Cl	171-173
2-Cl-Ph	H	CF ₃	156-158
2-Cl-Ph	OH	Cl	313-316
2-Cl-Ph	Cl	Cl	193-195
2-Cl-Ph	4-ethoxycarbonyl-piperazinyl	Cl	222-225
1-naphthyl	H	CF ₃	171-173
2-Cl-Ph	CH ₃	Cl	210-212
2-CH ₃ -5-iPrPh	CH ₃	Cl	141-142

-53-

	R ₃	R ₉	R ₁₃	m.p.(°C) or HRMS
5	2,6-(CH ₃) ₂ -Ph	CH ₃	Cl	HRMS Calcd. 462.0239. Found, 462.0369.
	2-(OC ₂ H ₅)-Ph	CH ₃	Cl	189.192
	2-(OC ₂ H ₅)-1-naphthyl	CH ₃	Cl	HRMS: Calcd.: 528.0345 Found: 528.0226
10	2-OCH ₃ -Ph	CH ₃	Cl	214-216
	2-C ₂ H ₅ -Ph	CH ₃	Cl	HRMS: Calcd. 462.0239 Found: 462.0219
	Ph	CH ₃	CF ₃	114-116
15	2,5-(CH ₃) ₂ -Ph	CH ₃	CF ₃	HRMS: Calcd. 497.0579 Found: 497.0602
	2-CF ₃ -Ph	CH ₃	Cl	HRMS: Calcd. 501.9800 Found: 501.9778

20

25


30

35

-54-

CLAIMS

1. A compound of the formula



10 wherein

A is C=O or SO₂, or A and R₁ together with the carbons to which they are attached form pyrimidinyl or 5-pyridyl which may be substituted by R₅ which is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, hydroxy, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), SH, S(O)_n(C₁-C₆ alkyl) wherein n = 0, 1 or 2, 15 wherein said C₁-C₆ alkyl may contain from one to two double or triple bonds and may be substituted by from 1 to 3 substituents R₆ which is hydroxy, amino, C₁-C₃ alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NH(C=O)CH₃, fluoro, chloro, bromo or C₁-C₃ thioalkyl.

R₁ is hydrogen, C₁-C₆ alkyl, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ 20 alkyl)(C₁-C₆ alkyl), wherein said C₁-C₆ alkyl may contain from one to two double or triple bonds and may be substituted by from 1 to 3 substituents R₆ as defined above;

R₂ is hydrogen, C₁-C₆ alkyl, hydroxy, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), SH, S(O)_n(C₁-C₆ alkyl) wherein n = 0, 1, or 2, cyano, hydroxy, carboxy, or amido, wherein said alkyls may be substituted by one to three 25 of hydroxy, amino, carboxy, amido, NH(C=O)(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), (C=O)O(C₁-C₆ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

R₃ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, 30 benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, pyridinyl, tetrazolyl, or 3 to 8-membered cycloalkyl or 9 to 12 membered

-55-

bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkanoyl, phenyl or phenylmethyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, trifluoromethyl, C₁-C₆ alkyl or C₁-C₆ alkoxy, or one of cyano, nitro, amino, NH(C₁-C₆ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NHSO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; and

10 R₄ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, pyridinyl, tetrazolyl, or 9 to 12-membered bicycloalkyl, optionally
15 containing one to three of O, S or N-Z wherein Z is hydrogen, C₁-C₄ alkyl, C₁-C₄ alkanoyl, phenyl or phenylmethyl, wherein each of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, trifluoromethyl, C₁-C₆ alkyl or C₁-C₆ alkoxy, or one of cyano, nitro, amino, NH(C₁-C₆ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NH₂SO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; provided that R₄ is not unsubstituted phenyl; and provided that when R₁ is amino, R₂ is methylthio, R₄ is 2,4,6-trichlorophenyl, and A is C=O, then R₃ is not 2-chlorophenyl.

25 2. A compound according to claim 1 wherein R₃ is phenyl substituted independently with one or two of fluoro, chloro, bromo, methyl, trifluoromethyl, nitro, C₁-C₆ alkyl, C₁-C₆ alkyloxy, SO₂NH₂, SO₂NH(C₁-C₆ alkyl), SO₂N(C₁-C₆ alkyl)₂, or R₃ is primary, secondary or tertiary alkyl of from 4-9 carbon atoms wherein said C₄-C₉ alkyl may contain from one to two double or triple bonds and may be substituted by from
30 1 to 3 substituents R₆ which is hydroxy, amino, C₁-C₃ alkoxy, dimethylamino, diethylamino, methylamino, thylamino, NH(C=O)CH₃, fluoro, chloro, bromo, r C₁-C₃ thioalkyl.

-56-

3. A compound according to claim 1 or 2 wherein R_4 is 2,4,6-trichlorophenyl, 2,4,6-trimethylphenyl, 2,6-dichloro-4-trifluoromethylphenyl or 4-bromo-2,6-dimethylphenyl.

4. A compound according to any one of claims 1 to 3 wherein R_1 is amino, methylamino or dimethylamino.

5. A compound according to any one of claims 1 to 4 wherein R_2 is methylthio or ethyl.

6. A compound according to any one of claims 1 to 5 where A is C=O.

7. A compound according to any one of claims 1, 2, 3 or 5 wherein A and R_1 together form a pyrimidine ring, such that the bicyclic structure formed is pyrazolo[3,4-d]pyrimidine, and R_5 is substituted at the 6 position.

8. A compound according to claim 1 wherein said compound is

[5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methylsulfanyl-1H-pyrazol-4-yl]-(2,5-dimethylphenyl)methanone,

15 [5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methylsulfanyl-1H-pyrazol-4-yl]-(2,5-bis-trifluoromethylphenyl)methanone,


[5-amino-1-(2,6-dichloro-4-trifluoromethylphenyl)-3-methylsulfanyl-1H-pyrazol-4-yl]-(5-isopropyl-2-methylphenyl)methanone,

20 [5-amino-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]-(5-isopropyl-2-methylphenyl)methanone, or

[5-amino-1-(4-bromo-2,6-dimethylphenyl)-3-methylsulfanyl-1H-pyrazol-4-yl]-(2,5-dibromophenyl)methanone.

9. A composition for the treatment of (a) illnesses induced or facilitated by corticotropin releasing factor or (b) stress-induced illnesses including stress-induced depression and headache, abdominal bowel syndrome, inflammatory disorders, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, particularly depression, which comprises a compound of the formula

-57-



5

wherein

- 10 A is C=O or SO₂, or A and R₁ together with the carbons to which they are attached form pyrimidinyl or 5-pyridyl which may be substituted by R₅ which is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, hydroxy, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), SH, S(O)_n(C₁-C₆ alkyl) wherein n = 0, 1 or 2, wherein said C₁-C₆ alkyl may contain from one to two double or triple bonds and may
- 15 be substituted by from 1 to 3 substituents R₆ which is hydroxy, amino, C₁-C₃ alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NH(C=O)CH₃, fluoro, chloro, bromo or C₁-C₃ thioalkyl.

 R₁ is hydrogen, C₁-C₆ alkyl, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), wherein said C₁-C₆ alkyl may contain from one to two double or

20 triple bonds and may be substituted by from 1 to 3 substituents R₆ as defined above;

 R₂ is hydrogen, C₁-C₆ alkyl, hydroxy, amino, O(C₁-C₆ alkyl), NH(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), SH, S(O)_n(C₁-C₆ alkyl) wherein n = 0, 1, or 2, cyano, hydroxy, carboxy, or amido, wherein said alkyls may be substituted by one to three

25 of hydroxy, amino, carboxy, amido, NH(C=O)(C₁-C₆ alkyl), N(C₁-C₆ alkyl)(C₁-C₆ alkyl), (C=O)O(C₁-C₆ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;

 R₃ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl,

30 pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrridinyl, thiazolidinyl, morpholinyl, pyridinyl, tetrazolyl, or 3 to 8-membered cycloalkyl or 9 to 12 membered bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen,

-58-

C₁-C₄ alkyl, C₁-C₄ alkanoyl, phenyl or phenylmethyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, trifluoromethyl, C₁-C₆ alkyl or C₁-C₆ alkoxy, or one of cyano, nitro, amino, NH(C₁-C₆ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl),
 5 SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NHSO₂(C₁-C₄ alkyl), S(C₁-C₆ alkyl), SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; and

R₄ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl,
 10 pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, pyridinyl, tetrazolyl, or 3 to 8-membered cycloalkyl or 9 to 12-membered bicycloalkyl, optionally containing one to three of O, S or N-Z wherein Z is hydrogen,
 15 C₁-C₄ alkyl, C₁-C₄ alkanoyl, phenyl or phenylmethyl, wherein each of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, trifluoromethyl, C₁-C₆ alkyl or C₁-C₆ alkoxy, or one of cyano, nitro, amino, NH(C₁-C₆ alkyl), N(C₁-C₄ alkyl)(C₁-C₂ alkyl), COO(C₁-C₄ alkyl), CO(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), SO₂NH₂, NH₂SO₂(C₁-C₄ alkyl),
 20 S(C₁-C₆ alkyl), SO₂(C₁-C₆ alkyl), wherein said C₁-C₄ alkyl and C₁-C₆ alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; provided that R₄ is not unsubstituted phenyl.

10. A method for the treatment of (a) illnesses induced by corticotropin releasing factor or (b) stress-induced illnesses including stress-induced depression
 25 and headache, abdominal bowel syndrome, inflammatory disorders, immune suppression, HIV infections, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction, and fertility problems, particularly depression, which comprises administering to a subject in need of such treatment a compound of formula I as defined in claim 9.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 93/10359

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07D231/44 C07D487/04 A61K31/415 C07D231/38 C07D231/18
C07D231/52 C07D403/10 C07D409/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 106, no. 7, 16 February 1987, Columbus, Ohio, US; abstract no. 50185s, page 642 ;column 2 ; see abstract and Chemical Abstracts 12th Collective Index; CHEMICAL SUBSTANCES; vol. 106-115; 1987-1991; pages 78256CS and 78260CS: RN [106258-97-3], [106259-60-3] and [106258-73-5] & EP,A,0 201 852 (BAYER AG) 20 November 1986 --- -/--	1-3

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

28 February 1994

Date of mailing of the international search report

- 9. 03. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Fink, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 93/10359

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 99, no. 11, 12 September 1983, Columbus, Ohio, US; abstract no. 88106s, page 562 ;column 2 ; see abstract and Chemical Abstracts 11th Collective Index; CHEMICAL SUBSTANCES; vol. 96-105; 1982-1986; page 58039CS and RN [86768-10-7] & ARCH. PHARM. vol. 316, no. 7 , 1983 , WEINHEIM, DE pages 608 - 616 ---	1,2,6
X	CHEMICAL ABSTRACTS, vol. 95, no. 5, 3 August 1981, Columbus, Ohio, US; abstract no. 43095p, page 43103 ;column 1 ; see abstract and Chemical Abstracts 10th Collective Index; CHEMICAL SUBSTANCES; vol. 86-95; 1977-1981; page 42017CS and RN [78065-81-3] & DE,A,30 25 579 (LABORATOIRE ROGER BELLON S.A.) 15 January 1981 ---	1,2
X	CHEMICAL ABSTRACTS, vol. 89, no. 25, 18 December 1978, Columbus, Ohio, US; abstract no. 215295y, page 586 ;column 1 ; see abstract and Chemical Abstracts 10th Collective Index; CHEMICAL SUBSTANCES; vol. 86-95; 1977-1981; page 31849CS and RN [68364-74-9], [68364-75-0] and [68364-73-8] & J. PRAKT. CHEM. vol. 320, no. 4 , 1978 pages 585 - 599 ---	1,2,4-6
X	JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1 no. 15 , 1974 , LETCHWORTH GB pages 1871 - 1875 T. NISHIWAKI ET AL. 'Studies on Heterocyclic Chemistry. Part XIX. Synthesis of 4-Aroyl-1-arylpyrazoles from alpha-Aroyl-beta-anilinoacrylonitriles and Photochemistry of 4-Carbonyl-substituted Pyrazoles' see page 1871, table: "5-Amino-4-aroyl-1-arylpyrazoles" , the last four entries see page 1874, column 1, paragraph 6 ---	1,2,4,6

-/--

INTERNATIONAL SEARCH REPORT

Inter. Patent Application No.
PCT/US 93/10359

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR,A,2 472 564 (LABORATOIRE ROGER BELLON) 3 July 1981 see page 24 - page 25; examples 13-17; table I see page 28, table IV, 1st entry see page 30, table IV, the last four entries -----	1,2
X	US,A,3 778 443 (V. P. ARYA) 11 December 1973 see column 24, line 39 - line 47 see column 25, line 7 - line 17 -----	1,2,6
A	US,A,5 063 245 (M.E. ABREU ET AL) 5 November 1991 cited in the application see the entire document; in particular columns 11-12, table I, entry 15 -----	1-10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/ 10359

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 10 is directed to a method of treatment of (diagnostic method of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

./.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/

The definition of the following substituent(s) is too general and/or encompasses too broad a range of totally different chemical groups, only partly supported by examples given in the descriptive part of the application:

R₃, R₄

The vast number of theoretically conceivable compounds resulting from the combination of all claimed substituents of above list precludes a comprehensive search. Guided by the spirit of the application and the inventive concept as disclosed in the descriptive part of the present application the search has been limited to the following case(s):

R₃, R₄ = opt. substituted phenyl or naphthyl

Claims searched incompletely: 1-7, 9, 10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/10359

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP-A-0201852	20-11-86	DE-A-	3602728	20-11-86
		AU-B-	580164	05-01-89
		AU-A-	5736886	20-11-86
		CA-A-	1296732	03-03-92
		JP-A-	61268671	28-11-86
		US-A-	4945165	31-07-90
		US-A-	4804675	14-02-89

DE-A-3025579	15-01-81	FR-A-	2460299	23-01-81
		BE-A-	884189	05-01-81
		CA-A-	1152507	23-08-83
		GB-A,B	2054566	18-02-81
		GB-A,B	2063870	10-06-81
		JP-A-	56015271	14-02-81
		NL-A-	8003888	07-01-81
		US-A-	4337263	29-06-82

FR-A-2472564	03-07-81	NONE		

US-A-3778443	11-12-73	NONE		

US-A-5063245	05-11-91	NONE		
